Holding(s) in Company

RNS Number : 6404K

Faron Pharmaceuticals Oy

10 July 2017

 

For filings with the FCA include the annex
For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii				Faron Pharmaceuticals Oy
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights					√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii		Aviva plc & its subsidiaries
4. Full name of shareholder(s)  (if different from 3.):iv		Registered Holder: Chase (GA Group) Nominees Limited            1,414,752* HSBC Global Custody Nominee (UK) Limited 347,410* State Street Nominees Limited                            35,452*             * denotes direct interest Chase (GA Group) Nominees Limited                 71,497 Chase Nominees Limited                                     41,687
5. Date of the transaction and date on which the threshold is crossed or reached: v		05 July 2017
6. Date on which issuer notified:		07 July 2017
7. Threshold(s) that is/are crossed or reached: vi, vii		7% to 6% Change at Combined Interest Level.  Figures are provided in accordance with provisions of your company articles and not in fulfilment of the requirements of the Transparency Directive.

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction				Resulting situation after the triggering transaction
	Number of Shares		Number of Voting Rights		Number of shares	Number of voting rights			% of  voting rights x
					Direct	Direct xi		Indirect xii	Direct		Indirect
Ordinary Shares FI4000153309	1,910,798		1,910,798		1,797,614	1,797,614		113,184	6.44%		0.41%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument		Expiration date xiii		Exercise/ Conversion Period xiv			Number of voting rights that may be acquired if the instrument is exercised/ converted.			% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx
					Nominal	Delta
Total (A+B+C)
Number of voting rights				Percentage of voting rights
1,910,798				6.85%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chains of controlled undertakings:- Aviva Investors Global Services Limited: ·      Aviva plc (Parent Company) ·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
10. Name of the proxy holder:	See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:	Figures are based on a total number of voting rights of  27,914,544 as per the company's Announcement of 1 June 2017.
14. Contact name:	Neil Whittaker, Aviva plc
15. Contact telephone number:	00 44 1603 684420

 

END

 

 

HOLDMGMNKGVGNZM